Aclaris Therapeutics, Inc. (ACRS) Stock Price & Analysis

Aclaris Therapeutics, Inc. (ACRS) rose 3.70% to USD 6.17 as of September 8, 2026 at 07:00 UTC, according to Nexqual real-time market data.

ACRS last closed at USD 6.17; the session ranged USD 5.87–6.2 on volume of 1,746,645 shares. Market capitalization is —, with a 52-week range of USD 1.74–6.6 (NMS). Source: Nexqual, September 8, 2026 at 07:00 UTC.

Key Statistics (as of September 8, 2026 at 07:00 UTC)

Technical Analysis (ACRS)

Nexqual's technical model rates ACRS "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 07:00 UTC.

From Aclaris Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• Our proprietary KINect drug discovery platform coupled with our integrated discovery approach to small and large molecules enables us to identify and advance product candidates designed to have superior target affinity, specificity and potency.
• We expect to file an IND application for ATI-9494 in the second half of 2026. ​ Discovery and Preclinical Programs ​ We conduct small molecule drug discovery through KINect, our proprietary drug discovery platform.
• We aim to take advantage of all of the intellectual property rights that are available to us and believe that this comprehensive approach will provide us with proprietary positions for our product candidates, where available. ​ We also protect our proprietary information by requiring our employees, consultants, contractors and other advisors to execute nondisclosure and assignment of invention agreements upon commencement of their respective employment or engagement.
• We are seeking to identify and consummate transactions with third-party partners to further develop, obtain marketing approval for and/or commercialize our novel product candidates. ​ Our Approach ​ We are dedicated to developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options .

Partnerships

• In addition, we also require confidentiality or service agreements from third parties that receive our confidential information or materials. ​ Acquisition and License Agreements ​ Exclusive License Agreement with Biosion ​ In November 2024, we entered into an exclusive license agreement (the "Biosion Agreement") with Biosion, pursuant to which we received exclusive rights to develop, manufacture and commercialize bosakitug and ATI-052 worldwide, excluding Greater China.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 07:00 UTC. This page is informational and not investment advice.